FDA-approved drug labeling for the study of drug-induced liver injury
about
MicroRNAs in Drug-induced Liver InjuryEvaluation of database-derived pathway development for enabling biomarker discovery for hepatotoxicityKey Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation PlansDrug-induced liver injury: Towards early prediction and risk stratificationTranslating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)PROXIMAL: a method for Prediction of Xenobiotic MetabolismA New Structure-Activity Relationship (SAR) Model for Predicting Drug-Induced Liver Injury, Based on Statistical and Expert-Based Structural AlertsDrug-induced liver injury: recent advances in diagnosis and risk assessment.Hepatotoxicity evaluation of traditional Chinese medicines using a computational molecular model.LTMap: a web server for assessing the potential liver toxicity by genome-wide transcriptional expression data.Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.DTNI: a novel toxicogenomics data analysis tool for identifying the molecular mechanisms underlying the adverse effects of toxic compounds.A computational toxicogenomics approach identifies a list of highly hepatotoxic compounds from a large microarray database.Two-photon fluorescent probe for revealing drug-induced hepatotoxicity via mapping fluctuation of peroxynitriteInsights into the molecular mechanisms of Polygonum multiflorum Thunb-induced liver injury: a computational systems toxicology approach.Prediction models for drug-induced hepatotoxicity by using weighted molecular fingerprints.In vitro platforms for evaluating liver toxicity.DEXUS: identifying differential expression in RNA-Seq studies with unknown conditionsInvestigating drug repositioning opportunities in FDA drug labels through topic modelingOf text and gene--using text mining methods to uncover hidden knowledge in toxicogenomicsMining FDA drug labels for medical conditionsA systems approach for analysis of high content screening assay data with topic modelingQuantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition.Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.ToxDB: pathway-level interpretation of drug-treatment dataSubtoxic Concentrations of Hepatotoxic Drugs Lead to Kupffer Cell Activation in a Human In Vitro Liver Model: An Approach to Study DILI.Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity.Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development.A decade of toxicogenomic research and its contribution to toxicological science.Hepatotoxicity: a scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action.Toward predictive models for drug-induced liver injury in humans: are we there yet?Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling.In Silico Identification of Proteins Associated with Drug-induced Liver Injury Based on the Prediction of Drug-target Interactions.A review of drug-induced liver injury databases.In silico Prediction of Drug-induced Liver Injury Based on Adverse Drug Reaction Reports.Current limitations and future opportunities for prediction of DILI from in vitro.LimTox: a web tool for applied text mining of adverse event and toxicity associations of compounds, drugs and genes.The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury.
P2860
Q26781801-11449A99-888E-4C4A-9A45-F3199ADDC3F2Q27027301-50A4597A-CE75-4303-8C4A-13AE2363FE65Q28075991-B54D4108-6A33-4A52-B097-F6F3004A3F27Q28468389-028397F1-3B58-47F1-9996-ECF95225D1E0Q28478443-B028DF6E-DCB3-45B6-B192-728E084A9F81Q28603730-7B26FF99-5B3F-4D14-9D98-36462118AC9BQ28820944-2DB3A730-FFFE-4437-BFCC-7EAEA0B05568Q30235089-5344BCC7-0384-45F6-BD3E-DF0A86BD0097Q30491931-BE0F0CC2-F3B7-4554-84C8-F52C3764A75CQ30666142-45C5EA32-0049-4DDC-BB09-445D8DFCBA62Q30838395-7C12C8FB-E9C1-4017-9137-1FE96AA00A03Q31151887-B12641C8-360E-45E5-B5F2-617119A06158Q33610772-1726EED4-5816-406D-B3A3-E9A9EDFFE6BEQ33697607-25C0750A-C776-48A3-8BDA-07558A198355Q33759927-620A727B-A7C5-41DB-B5ED-E96AEA29FFFBQ33802204-E7B9E308-18E4-4CE7-BD71-C5BA9C4D985BQ34143314-195030DE-ED1F-4641-93CF-D90A21114B35Q34372165-2FFF9D28-EB12-4B5E-8A9A-92B16E01A11FQ34436688-536521C9-CDA7-4094-8915-222B604AACBCQ34538839-AE2C141E-11A9-46E9-90F2-F71C4C92212EQ34686845-B243B1B8-9B22-4A59-A729-706963441B0DQ35051254-95DEA1D2-5EE8-432E-B0A8-01C2334118B6Q35185827-1E7B9946-3487-4C95-87B0-DDCB53627BB3Q35819331-DFA91FA1-522D-4EA0-A1BB-0E685F5FAED1Q35988782-BEFEFB93-B65E-440F-BE4E-47EE2875556BQ36146271-5CD7FE5E-F3F6-4A62-BB3C-C7D13B8FF720Q37380777-A0F55BC5-3177-44D4-B21C-7251C6EB7325Q37590883-92FF578B-132F-4019-A152-B2B6987BAF0BQ37603877-BC8DF5EF-55C9-4A3E-9C1B-74C76C3EE407Q37975546-0CD42AB7-D14D-48C9-A2A8-DA9BD6883D09Q38025961-347FAE89-AE27-46DF-8FA7-28D9F1F61C4FQ38123214-CC2CAAA3-B3EE-4D8D-B128-F6DFF2544707Q38187450-D3F55DDE-4BBF-40EA-AB07-F2BFAB51D4E8Q38363295-AB07618E-2B31-4507-B3C5-C0182FFC2E8CQ38437547-C2F704C6-8F5C-4B1D-AF97-98DF40F106C7Q38674530-2D678A32-0150-40E0-B757-AF691AB394E4Q38682276-923D7636-C9AF-4F20-8DDA-DEE044760595Q38739197-0A95D9C1-3A88-4042-BA6B-8375BFA473C4Q38771016-7E077ABB-C0A8-40A1-8180-F254CAC90035Q38782421-EF944298-BA55-4ED6-8AD0-C69073287466
P2860
FDA-approved drug labeling for the study of drug-induced liver injury
description
article
@en
im August 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2011
@uk
name
FDA-approved drug labeling for the study of drug-induced liver injury
@en
FDA-approved drug labeling for the study of drug-induced liver injury
@nl
type
label
FDA-approved drug labeling for the study of drug-induced liver injury
@en
FDA-approved drug labeling for the study of drug-induced liver injury
@nl
prefLabel
FDA-approved drug labeling for the study of drug-induced liver injury
@en
FDA-approved drug labeling for the study of drug-induced liver injury
@nl
P2093
P1433
P1476
FDA-approved drug labeling for the study of drug-induced liver injury
@en
P2093
Minjun Chen
Zhichao Liu
P304
P356
10.1016/J.DRUDIS.2011.05.007
P577
2011-08-01T00:00:00Z